ビタミンK1

Vitamin K

HCID 5280483

基本情報

CAS
12001-79-5
標準SMILES
CC1=C(C/C=C(\C)CCCC(C)CCCC(C)CCCC(C)C)C(=O)c2ccccc2C1=O
InChIKey
MBWXNTAXLNYFJB-LKUDQCMESA-N
分子式
C31H46O2
平均分子量
450.7 g/mol
単同位体質量
450.34978071

概要

2-methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)naphthalene-1,4-dione is a member of 1,4-naphthoquinones.

名称と識別子

優先名称
Vitamin K
IUPAC
2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
現地名
ビタミンK1
英語名
VITAMIN K1
分子式
C31H46O2
分子量
450.7

名称と別名

VITAMIN K12001-79-5DTXSID1052743RefChem:934090CHEBI:28384234-408-72-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione.alpha.-PhylloquinonePhythyl-menadion2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dioneMFCD000016833-methyl-2-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
名称をさらに表示
ビタミンKビタミンK1vitamine K6E)-1C01628KanavitSynkavite7-Diphenyl-4VITAMIN K1 USP236-heptadien-3-oneVitamin K substances
2-methyl-3-[(2E)-3,7,11,15-tetramethylhexadec-2-en-1-yl]-1,4-dihydronaphthalene-1,4-dione2581046-19-527696-10-2C31H46O2EINECS 279-833-9(E)-2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione(E)-2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione13-((2E)-3,7,11,15-tetramethylhexadec-2-enyl)-2-methylnaphthalene-1,4-dione

データベース識別子

CAS
12001-79-5、27696-10-2、79083-00-4、81818-54-4、84-80-0
PubChem CID
5280483
DTXSID
DTXSID501369321
ChEMBL
CHEMBL520156
ChEBI
CHEBI:94399
EC Number
234-408-7、279-052-3
Nikkaji
J20.960K、J3.787.784K

物性

構造計算による物性

XLogP
10.9
極性表面積
34.1 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
14
重原子数
33

実験および物理化学的性質

DrugsPharmaceuticals
Food AdditivesNUTRIENT SUPPLEMENT -> FDA Substance added to food
Dietary IngredientsVitamin K
Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Vitamins; Antifibrinolytic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

物理化学的性質

融点
20 °C · −20 °C(lit.)
比重(密度)
0.984 g/mL · 0.984 g/mL at 25 °C(lit.)
屈折率
20 · n20/D 1.527(lit.)
闪点
230 °F · >230 °F
貯蔵温度
2 · 2-8°C
溶解性
Soluble in DMSO

安全と法規制

危険有害性情報

Regulatory Information · 2 件

Chemical: Vitamin K

Vitamin K: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationEvaluation - Chemicals not considered for in depth evaluation - Not commercially active in Australia

毒性情報

Adverse Effects · 1 件

Currently, there is no known toxicity is associated with high doses of vitamin K1 or vitamin K2. Therefore, there is no designated upper intake level (UL). Despite this, an allergic reaction is possible with either version of vitamin K. Vitamin K1 has had documented associations with bronchospasm and cardiac arrest with IV administration. The oral form of vitamin K does not seem to cause severe reactions.

Exposure Routes · 1 件

Subcutaneous, Intramuscular, Intravenous injection. Oral phylloquinone is adequately absorbed from the gastrointestinal tract only if bile salts are present. After absorption, phylloquinone is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues.

Toxicity Summary · 2 件

Vitamin K toxicity is extremely rare. The only reported toxicity comes from menadione, which has no use in humans. Its toxicity is thought to be associated with its water-soluble properties. When toxicity does occur, it manifests with signs of jaundice, hyperbilirubinemia, hemolytic anemia, and kernicterus in infants.

Vitamin K is an essential cofactor for the gamma-carboxylase enzymes which catalyze the posttranslational gamma-carboxylation of glutamic acid residues in inactive hepatic precursors of coagulation factors II (prothrombin), VII, IX and X. Gamma-carboxylation converts these inactive precursors into active coagulation factors which are secreted by hepatocytes into the blood. Supplementing with Phylloquinone results in a relief of vitamin K deficiency symptoms which include easy bruisability, epistaxis, gastrointestinal bleeding, menorrhagia and hematuria.

Carcinogen Classification · 6 件

Vitamin K substances

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 76: (2000) Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents

2000

1999

3, not classifiable as to its carcinogenicity to humans. (L135)

Effects During Pregnancy and Lactation · 2 件

◉ Summary of Use during Lactation

◈ What is vitamin K?

Toxicity DataLD50: 41.5 mL/kg at 0.2% (Intravenous, Mouse) (A308) LD50: 52 mL/kg at 1% (Intravenous, Mouse) (A308)

安全データ

F
1-8-10
wgk
2
tsca
TSCA listed
rtecs
QJ5800000
毒性
mouse,LD50,subcutaneous,700mg/kg (700mg/kg),Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 25, 1958.

化学と産業

薬理情報

Metabolism/MetabolitesRoute of Elimination: Almost no free unmetabolized vitamin K appears in bile or urine.
MeSH Pharmacological Classification · 2 件

Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.

Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body.

用途と製造

UsesFor the treatment of haemorrhagic conditions in infants, antidote for coumarin anticoagulants in hypoprothrombinaemia.
General Manufacturing InformationVitamin K: INACTIVE
応用分野 · 1 件

解説フィロキノンともいう.血液凝固を促進する脂溶性ビタミン.血液凝固に必要な因子のⅡ因子(プロスロンビン)やⅦ因子,Ⅸ因子,Ⅹ因子の生合成に関係する.凝固(Koagulation,独語)のKをとって命名された.1939年,E.A. Doisy(ドイジー)らは,アルファルファ(牧草)と腐敗魚粉から2種類のビタミンK物質を分離して,ビタミン K1,K2 と命名した.これらの物質がキノン構造を有することを推定して,数多くのキノノイドについて検討し,2-メチル-1,4-ナフトキノンが有効であることを明らかにした."これが現在ビタミン K3 とよばれているものである.いずれも水に不溶,有機溶媒に可溶.光,アルカリなどによって容易に分解される.空気,湿気に対しては比較的安定である.なお,出血剤ジクマロールはビタミンKのアンチビタミンである.ビタミン K1:フィロキノン,フィトナジオン,2-メチル-3-フィチル-1,4-ナフトキノンともいう.C31H46O2(450.17).鮮黄色の油.融点-20 ℃.紫外線照射により変性する紫外線.照射により殺菌された牛肉でネズミを飼育すると,ビタミンK欠乏症を示した.森北出版「化学辞典(第2版)

関連反応

3 件

化合物ノート

読み込み中…